{
  "docId": "019de070-a7f9-700d-9686-c0d9e2559ea7",
  "docSlug": "49e1302a11c2e640ac427a516c932653",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 82 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 29,
  "pageCount": 82,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a timeline-like structure to present upcoming clinical trial milestones and recent COVID-19 treatment developments.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-a7f9-700d-9686-c0d9e2559ea7/29",
  "deckHref": "/decks/019de070-a7f9-700d-9686-c0d9e2559ea7",
  "deckJsonHref": "/decks/019de070-a7f9-700d-9686-c0d9e2559ea7.json",
  "deckAnchorHref": "/decks/019de070-a7f9-700d-9686-c0d9e2559ea7#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.0023
      },
      "kind": "callout",
      "text": "NOV03 SEECASE Study Published in The Journal of Cornea and External Disease: Study met its primary endpoint, change from baseline of tCFS over control, for both dosing regimens QID and BID.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c62992d7-cf44-491f-9324-fa1afae84883",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.04,
        "y": 0.0023
      },
      "kind": "list",
      "text": "Initiate Amiselimod S1P2 Modulator Phase 2 trial; Readout of NOV03 Phase 3; Initiate Phase 3 for rifaximin; Initiate Phase 2 for rifaximin; Complete enrollment for Eyenovia; Start Phase 3 for Risuteganib.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c1be4a9-90a0-4f60-9b2b-9b8cd60b8d75",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.04,
        "y": 0.0060999999999999995
      },
      "kind": "paragraph",
      "text": "COVID Focused Treatments: DEXAVEN, LUMIFY, BESIVANCE, Opcon-A, IVEXTERM, VIRAZOLE updates.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e784aa49-8fc9-493c-ad89-86aed178a281",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.0016
      },
      "kind": "paragraph",
      "text": "R&D: Upcoming Milestones",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb8d482b-be1a-4440-b587-1d9bfe7906b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.25,
        "y": 0.009
      },
      "kind": "source-note",
      "text": "Footnotes 1-11 detailing clinical trial and licensing information.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f07abeaf-48f5-4146-aefb-31362728230d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Near-term Catalysts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b71db1ee-badc-4c5e-b1ed-973f8520189c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "6df21fef-3b86-447d-bbb9-b93164910bbe",
      "evidence": "The slide organizes R&D milestones by expected timeframes (1H21, 2H21, 2H22).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3f929d33-08a9-4163-8b41-a09e812667a2",
      "evidence": "The presentation emphasizes the importance of execution, growth, and accelerating strategic alternatives.",
      "position": 0,
      "objective": "Highlighting the cost of inaction and the benefits of strategic alternatives",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 32,
      "from": 29,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "cd630bab-376c-4464-8a9b-5dddbbd90c84",
      "evidence": "The presentation outlines near-term catalysts and a roadmap for growth and strategic focus.",
      "position": 1,
      "objective": "Presenting near-term catalysts and a roadmap for growth",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}